Expect sharp downside pressure as guidance cuts confirm deteriorating demand and execution. Monitor the May 6 earnings call for details on cost actions and B Medical sale timeline. The lack of buyback execution despite authorization suggests management priorities elsewhere.
Price Chart
Executive Summary
Azenta reported Q2 FY2026 revenue of $145M (+1% reported, -3% organic), non-GAAP EPS of ($0.04) vs $0.01 a year ago, and a $149M goodwill impairment. FY2026 guidance was sharply cut: organic revenue now expected -2% to +1% (prior 3-5% growth) and Adjusted EBITDA margin expected -125bps to flat (prior +300bps expansion). Long-range plan extended to 2029, and B Medical Systems sale remains uncertain. The filing signals worsening demand and execution issues.
Key Financial Metrics
Key Facts
- Q2 FY2026 revenue: $145M, up 1% YoY reported, organic down 3%
- GAAP diluted EPS from continuing ops: ($3.41) vs ($0.43) YoY, including $149M goodwill impairment
- Non-GAAP diluted EPS: ($0.04) vs $0.01 YoY
- FY2026 organic revenue guidance lowered to -2% to +1% from prior 3-5% growth
- FY2026 Adjusted EBITDA margin outlook cut to -125bps to flat from prior +300bps expansion
- Long-range plan extended from 2028 to 2029
- B Medical Systems sale delayed; buyer has not secured financing
- No share repurchases executed under $250M program
Financial Impact
Goodwill impairment of $149M; guidance revision implies $30-40M revenue reduction vs prior outlook
Risk Factors
- Further demand weakening in life sciences tools market
- B Medical Systems sale falling through, requiring additional cash outflows or write-downs
- Additional impairment charges if revenue trends continue declining
- Dilution from potential equity offering if cash needs arise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-030677 |
| Document: azta-20260505.htm | 0001628280-26-030677 |
| Document: 0001628280-26-030677-index-headers.html | 0001628280-26-030677 |
| Document: 0001628280-26-030677-index.html | 0001628280-26-030677 |
| Document: 0001628280-26-030677.txt | 0001628280-26-030677 |
| 8-K Data (Synthetic) | 0001628280-26-030677 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 8-K | $31.33 $32.04 | ▲ +2.27% | ▲ +3.48% | $38.75 (+23.68%) |
Aug 24, 2026 5w ago | 8-K | $32.88 $32.65 | ▼ −0.70% | ▼ −1.17% | $38.75 (+17.85%) |
Aug 8, 2026 7w ago | Institutional Cluster | $33.33 $33.58 | ▲ +0.75% | ▲ +0.80% | $38.75 (+16.26%) |
Aug 4, 2026 8w ago | Press Release | $31.82 $33.53 | ▲ +5.37% | ▲ +5.02% | $38.75 (+21.78%) |
Jul 8, 2026 12w ago | 8-K | $24.51 $25.44 | ▲ +3.79% | ▲ +2.93% | $38.75 (+58.10%) |
May 5, 2026 21w ago | 8-K | $18.38 $17.53 | ▲ +4.62% | ▲ +5.76% | $38.75 (−110.83%) |
Apr 7, 2026 25w ago | 8-K | $21.71 $24.26 | ▲ +11.75% | ▲ +6.42% | $38.75 (+78.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access